Management of refractory mantle cell lymphoma MEDSTAT_JS MEDSTAT_CSS

Management of refractory mantle cell lymphoma

“Refractory” mantle cell lymphoma (MCL) refers to when the disease does not respond to treatment, or the response does not last long. Dr. Jacqueline Barrientos recently led a discussion with Dr. Peter Martin and Dr. Michael Wang, in which the panel reviewed clinical trial data for new later-line therapies, how to identify higher-risk patients, and what role minimal residual disease (MRD) may play in the future.

Video 1: Current state of management

The panel sets the stage with a brief look at exciting front-line treatment advances coming out of ASH 2020 before reviewing promising data surrounding LOXO-305 and CAR-T agents in patients who had prior resistance to BTK inhibitors.

Up Next

Video 1: Current state of management
Video 2: Identifying high-risk patient populations
Video 3: Looking ahead at the role of MRD

MEDSTAT_LATEST_NEWS_WIDGET

About the Panel

Dr. Barrientos Photo

Jacqueline C. Barrientos, MD, MS

  • Associate Professor,
  • Zucker School of Medicine at Hofstra/Northwell,
  • Hempstead, NY
Dr. Martin Photo

Peter Martin, MD

  • Associate Professor,
  • Weill Cornell Medicine,
  • New York, NY
Dr. Wang Photo

Michael Wang, MD

  • Professor,
  • MD Anderson Cancer Center,
  • Houston, TX
Disclosures

Jacqueline C. Barrientos, MD, MS, has disclosed the following relevant financial relationships:
Research funding: AstraZeneca, Oncternal, TG therapeutics, Pharmacyclics/Abbvie. Ad Board: AstraZeneca, Pharmacyclics/Abbvie, Beigene, Genentech, Gilead, Innate

Peter Martin, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: ADCT; Bayer; Beigene; Bristol-Myers Squibb; Cellectar; Gilead; Janssen; Karyopharm; Morphosys; Regeneron; Teneobio; Verstem
Received research grant from: Karyopharm

Michael Wang, MD, has disclosed the following relevant financial relationships:
Research grants: Janssen, Pharmacyclics, AstraZeneca, Acerta Pharma, Celgene, Juno Therapeutics, BeiGene, Kite Pharma, Loxo Oncology, VelosBio, BioInvent, Molecular Templates, Oncternal, InnoCare, Lilly.
Consulting/advisory board: Loxo Oncology, Janssen, Pharmacyclics, Celgene, Juno Therapeutics, Kite Pharma, AstraZeneca, Acerta Pharma, Genentech, Cstone, Innocare, Oncternal, Bayer Healthcare.
Honoraria: Janssen, Acerta Pharma, OMI, Physicians Education Resources (PER), Dava Oncology, CAHON, Hebei Cancer Prevention Federation, Clinical Care Options, Mumbai Hematology Group, Anticancer Association.